BioCentury
ARTICLE | Company News

Merck ends AD deal with Acumen

December 22, 2011 1:21 AM UTC

Acumen Pharmaceuticals Inc. (Livermore, Calif.) said Merck & Co. Inc. (NYSE:MRK) terminated a 2003 deal and returned rights to develop and commercialize anti-amyloid-derived diffusible ligand (ADDL) antibody therapeutics and diagnostics for Alzheimer's disease. According to Acumen, Merck made the decision based on "internal strategic priorities." Acumen said the program is in preclinical testing. ...